Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Gavin S. Choy"'
Autor:
Sonia Kumar, Sufia Safina, H Rugo, Adamm Hamm, Elizabeth A. Mittendorf, Mark Ahn, Gavin S. Choy, Michelle E. Melisko, Katarína Petráková, Lacey Chance, Maria Litwiniuk, John R. Mackey, Michael Schenker, Svitiana Alieva, Murray A Brunt
Publikováno v:
Cancer Research. 75:P2-15
Background : The distinction between HER2-positive (IHC 3+ or 2+ with FISH ratio >/= 2) and not overexpressing HER2 has been the focus of many diagnostic tests over the past years in association with development of HER2-targeted therapies. The paucit
Autor:
Jessica Tang, Jay Pilrose, Mohammad Azab, Daniela Matei, Kenneth P. Nephew, John J. Turchi, Pamela S. VanderVere-Carozza, Michael W. Wagner, Pietro Taverna, Gavin S. Choy, Joanne M. Munck, David F.B. Miller, Yinu Wang, Katherine S. Pawelczak, John Lyons, Fang Fang
Publikováno v:
Clinical Cancer Research. 20:6504-6516
Purpose: To investigate SGI-110 as a “chemosensitizer” in ovarian cancer and to assess its effects on tumor suppressor genes (TSG) and chemoresponsiveness-associated genes silenced by DNA methylation in ovarian cancer. Experimental Design: Severa
Autor:
Xiaoling Zhang, Qian Shi, Gavin S. Choy, Sanjeev Redkar, Mamatha Reddy, Lan Yang, Elaine Liu, Tillman E Pearce
Publikováno v:
Cancer Research. 79:2205-2205
Background: The role of the tumor microenvironment (TME) in fostering the development of malignancies is prompting the pursuit of anticancer therapies that target its components as to opposed to the tumor itself. As part of their immune surveillance
Autor:
Mamatha Reddy, Zhao Wei, Gavin S. Choy, Ling Yang, Sanjeev Redkar, Zhun Wang, Jiansheng Lu, Yingchun Li, Xiquan Zhang, Junzhuan Qiu, Tian Xin, Ziyong Sun, Jiping Zha
Publikováno v:
Molecular Cancer Therapeutics. 17:A200-A200
Background: CBT-502 (TQB2450) is a novel humanized IgG1 antibody against programmed cell death-ligand 1(PD-L1) developed by CBT Pharmaceuticals, Inc. CBT-502 shows significant sequence divergence in CDRs from other anti-PD-L1 antibodies in the market
Publikováno v:
Cancer Research. 77:2096-2096
Background: cMET is a receptor tyrosine kinase that is located on the cell surface and is activated by the binding of its ligand, hepatocyte growth factor (HGF). In cancer cells, MET can be aberrantly active and cause abnormal signaling, which leads
Publikováno v:
Journal of Clinical Oncology. 35:108-108
108 Background: CBT-501 (Genolimzumab, GB-226) is a novel humanized mAb (IgG4k) against human Programmed Death-1 (PD-1). CBT-501 demonstrated highly specific binding to PD-1 of human (KD= 505 pM) and cynomolgus (KD= 7.2 nM). It did not completely blo
Publikováno v:
Journal of the American Geriatrics Society. 45:211-214
OBJECTIVE: To assess the potential benefit of a pharmacist performing in-home medication evaluations on frail older people. DESIGN: Prospective analysis with pre-post comparison. SETTING: A hospital-based home care program at the Sepulveda Veterans A
Autor:
Shalabh Sachdeva, Palepu Jagannath, Gavin S. Choy, Shyam Parvatini, Ashis Patnaik, Akhilesh D. Sharma
Publikováno v:
Journal of Clinical Oncology. 34:18-18
18 Background: Gastric cancer remains a major health issue and results in 800,000 annual deaths worldwide. Despite approximately 50% of the gastric and gastroesophageal (GE) junction adenocarcinomas are diagnosed with resectable disease, 40% of disea
Publikováno v:
Journal of Clinical Oncology. 34:e274-e274
e274 Background: According to the NCI Office of Cancer Survivorship, in 2014, it is estimated there are 14.5 million cancer survivors in the US. By 2024, it is projected there will be 19 million cancer survivors. Peptide-based vaccines are being deve
Autor:
Phu V. Troung, Olivier Barriere, Srdan Verstovsek, Gavin S. Choy, Dmitriy Berenzon, Raul Mena, Nasiema Wingate-Pearse, Paul F. Glidden, Marc Saltzman, William Jawien, Roger M. Lyons, Alberto Bessudo, Hali E. Beeson
Publikováno v:
Blood. 126:4074-4074
Introduction: Agrylin® (United States) and Xagrid® (European Union) are immediate release (IR) preparations of anagrelide hydrochloride that block megakaryocyte differentiation and proliferation and inhibit the action of cyclic AMP phosphodiesteras